Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HALT-BC: Denosumab for AI-induced bone loss
NCT00089661Phase 3Completed
- Sponsor
- Amgen
- Start
- Oct 2004
- Primary completion
- May 2007
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 3 trial of denosumab in osteopenia, osteoporosis, sponsored by Amgen. Started Oct 2004; status: completed.
02
Drugs
denosumab
03
Conditions
osteopeniaosteoporosis
Beyond the preview
Go deeper on NCT00089661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00089661.